About GT Medical Technologies
GT Medical Technologies is a company based in Tempe (United States) founded in 2017 by Theresa Thomas, Emad Youssef, David G Brachman, Heyoung McBride, and Peter Nakaji. GT Medical Technologies has raised $129.94 million across 7 funding rounds from investors including Horizon Tech Finance, MVM Partners and Gilde Healthcare. GT Medical Technologies offers products and services including GammaTile Therapy. GT Medical Technologies operates in a competitive market with competitors including HEPTA Medical, Curative Biotech, Laevoroc Oncology, Rongsheng Medical and InCephalo, among others.
- Headquarter Tempe, United States
- Founders Theresa Thomas, Emad Youssef, David G Brachman, Heyoung McBride, Peter Nakaji
- SectorsHealthcare
- Website gtmedtech.com
- Social LinkedIn X YouTube
- Total Equity Funding$129.94M (USD)
in 7 rounds
- Latest Funding Round$53.3M (USD), Series C
Dec 2024
- InvestorsHorizon Tech Finance
& 6 more
Products & Services of GT Medical Technologies
GT Medical Technologies offers a comprehensive portfolio of products and services, including GammaTile Therapy.
Surgically targeted radiation to treat brain tumors and minimize side effects
Apps and channels of GT Medical Technologies
its YouTube channel GammaTile | Brain Tumor Treatment has 264 subscribers and 30 videos.
Videos from GT Medical Technologies
The most watched videos on GT Medical Technologies's YouTube channel, GammaTile | Brain Tumor Treatment (264 subscribers). Click a video to play it here.
More on GammaTile | Brain Tumor Treatment.
Funding Insights of GT Medical Technologies
GT Medical Technologies has successfully raised a total of $129.94M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $53.3 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $129.94M
- Total Rounds 7
- Last Round Series C — $53.3M
- First Round $510,000
(Dec 2017)
- Investors Count 7
All 7 funding rounds of GT Medical Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $53.3M | Series C | – | Evidity Health Capital | |
| Sep 2024 | $35M | Debt – Venture | – | – | |
| Mar 2023 | $45M | Series C | – | Gilde Healthcare | |
| Nov 2020 | $16M | Series B | – | MVM | |
| Jan 2019 | $10M | Series A | – | Medical Technology Venture Partners | |
| Nov 2018 | $5.64M | Series A | – | – | – |
| Dec 2017 | $510,000 | Debt – Conventional | – | – | – |
7 investors in total: 7 institutional.
Investors in GT Medical Technologies
GT Medical Technologies has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Horizon Tech Finance, MVM Partners and Gilde Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Structured debt is provided to life sciences and technology firms. | 2004 | horizontechfinance.com | Farmington, United States | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
MedTech Venture Partners is focused on medical technology investments. | – | medtechvp.com | Menlo Park, United States | |
- | – | bluestonevp.com | - | |
Late-stage venture capital and growth equity investments are managed by Evidity Health Capital. | – | evidity.com | New York, United States | |
- | – | accelmed.com | - |
Investor details for GT Medical Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GT Medical Technologies
35 people are tracked at GT Medical Technologies (22 in leadership, 13 in team).
| Name | Role | Group |
|---|---|---|
Theresa Thomas | Co-Founder | Leadership |
Emad Youssef | Co-Founder | Leadership |
David G Brachman | Co-Founder | Leadership |
Heyoung McBride | Co-Founder | Leadership |
Peter Nakaji | Co-Founder | Leadership |
Michael Garcia | Chief Medical Officer | Leadership |
Rich Low | Chief Marketing Officer | Leadership |
Gina Orofino | Area Director - Western Region | Leadership |
Jeff Lewis | Chief Commercial Officer | Leadership |
Tim Frandsen | Head Of Market Development | Leadership |
Danielle Hazarian | Senior Director Of Global Marketing | Leadership |
Matthew E. Likens | President & CEO | Leadership |
Tom Moore | Chief Commercial Officer (cco) | Leadership |
Adam Turner | Vice President Of Scientific Affairs | Leadership |
Ty Atteberry | Vice President Of Sales | Leadership |
David Brachman M.D. | Chief Technology Officer | Leadership |
Joe Badolato | Senior Regional Sales Director | Leadership |
Anthony Smith | Senior Vice President Operations | Leadership |
Meg Gardner | Director | Leadership |
Sita P. | Director Of Clinical Affairs | Leadership |
15 more people are available in the full profile.
Complete people profiles for GT Medical Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GT Medical Technologies
3 dated milestones of GT Medical Technologies across 7 years, from founding to its latest funding, stage changes and deals.
- Founded GT Medical Technologies is founded.
- Funding First funding round of $510K.
- Funding Latest funding round, Series C, of $53.3M.
Competitors of GT Medical Technologies
GT Medical Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HEPTA Medical, Curative Biotech, Laevoroc Oncology, Rongsheng Medical and InCephalo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| heptamed.com | 2018 | Paris, France | $6.3M | – | Minimally invasive ablation catheters for pulmonary nodules are developed endoscopically. | |
| curativebiotech.com | 1995 | Boca Raton, United States | – | – | Therapeutic drugs for cancer, eye, and infectious diseases are developed. | |
| laevoroc.com | 2019 | Hunenberg, Switzerland | $1.1M | – | Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed. | |
| rongshengmedical.tcc.mode | 2019 | Suzhou, China | – | – | Developer of precision internal radiation interventional therapy for tumors | |
| incephalo.com | 2021 | Allschwil, Switzerland | – | – | Therapeutics for neurological disorders are developed using barrier-retaining technology. | |
| seguetx.com | 2016 | New Orleans, United States | $170,000 | – | Proprietary high content imaging platform to discover and commercialize repurposed drugs for the treatment of cancer, fibrosis and fungal infections | |
| vyrobio.com | 2021 | Sao Paulo, Brazil | – | – | Oncolytic virus drugs are developed for central nervous system tumors. |
Detailed competitors of GT Medical Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GT Medical Technologies
The website of GT Medical Technologies (gtmedtech.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 14.5% vs previous month
Latest news on Gt Medical Technologies
Complete news archive for GT Medical Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to GT Medical Technologies
10 companies that operate in the same segment as GT Medical Technologies (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GT Medical Technologies
GT Medical Technologies was founded in 2017.
GT Medical Technologies is headquartered in Tempe, United States. It is registered at Tempe, Arizona, United States.
GT Medical Technologies is a funded company, having raised a total of $129.94M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $510K, raised on Dec 2017.
GT Medical Technologies providers medical devices for radiation therapy for brain tumor treatment. It offers GammaTile Therapy is surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors. The technology uses a combination of a collagen matrix with brachytherapy (radiation) seeds. The technology of the compnay is protected by 10 US and 2 Canadian issued patents, and 1 EPO patent.
GT Medical Technologies's top competitors include Laevoroc Oncology, HEPTA Medical and Curative Biotech.
GT Medical Technologies offers GammaTile Therapy.
GT Medical Technologies has 7 investors. Key investors include Horizon Tech Finance, MVM Partners, Gilde Healthcare, MedTech Venture Partners, and BlueStone Venture Partners.